Verrica Pharmaceuticals Inc.
VRCA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | -0.05 | 0.09 | 0.29 |
| FCF Yield | -168.08% | -11.73% | -20.17% | -11.49% |
| EV / EBITDA | -0.54 | -4.95 | -2.83 | -9.08 |
| Quality | ||||
| ROIC | -170.21% | -100.74% | -51.24% | -40.66% |
| Gross Margin | 75.51% | 85.44% | 91.97% | 96.07% |
| Cash Conversion Ratio | 0.80 | 0.58 | 0.76 | 0.79 |
| Growth | ||||
| Revenue 3-Year CAGR | -5.73% | -24.70% | – | – |
| Free Cash Flow Growth | -56.54% | -105.46% | 33.42% | 10.14% |
| Safety | ||||
| Net Debt / EBITDA | 0.01 | 0.39 | 1.52 | -0.91 |
| Interest Coverage | -7.00 | -16.60 | -9.80 | -7.20 |
| Efficiency | ||||
| Inventory Turnover | 0.75 | 0.73 | 0.00 | 0.00 |
| Cash Conversion Cycle | 115.40 | -390.97 | -235.57 | -653.44 |